OPOR.F Stock Overview
Operates as a pharmaceutical service and contract research company in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
hVIVO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.37 |
| 52 Week High | UK£0.37 |
| 52 Week Low | UK£0.33 |
| Beta | 0.97 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19,003.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| OPOR.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | 0.3% |
| 1Y | n/a | 3.1% | 31.1% |
Return vs Industry: Insufficient data to determine how OPOR.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how OPOR.F performed against the US Market.
Price Volatility
| OPOR.F volatility | |
|---|---|
| OPOR.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OPOR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine OPOR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 274 | Mo Khan | www.hvivo.com |
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations.
hVIVO plc Fundamentals Summary
| OPOR.F fundamental statistics | |
|---|---|
| Market cap | US$194.95m |
| Earnings (TTM) | US$21.83m |
| Revenue (TTM) | US$84.10m |
8.9x
P/E Ratio2.3x
P/S RatioIs OPOR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPOR.F income statement (TTM) | |
|---|---|
| Revenue | UK£67.21m |
| Cost of Revenue | UK£50.65m |
| Gross Profit | UK£16.56m |
| Other Expenses | -UK£884.00k |
| Earnings | UK£17.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.026 |
| Gross Margin | 24.64% |
| Net Profit Margin | 25.96% |
| Debt/Equity Ratio | 0% |
How did OPOR.F perform over the long term?
See historical performance and comparison